Current Size: 100%

News

ERIA meeting in Monza, Italy

The European Research Initiative on Anaplastic lymphoma kinase (ALK)-related malignancies (ERIA) celebrated the twentieth anniversary of the discovery of ALK at its annual meeting in Monza on June 20-21, 2014. The meeting was attended by Prof Tom Look (Dana Faber Institute, Harvard), the co-discoverer of the fusion gene NPM-ALK in lymphomas, and Dr. Robert Ghelfi (Pfizer), who developed the first compound to inhibit ALK, crizotinib.

Annual Review Meeting celebrates the integration of the LBI-CR with partners

The annual review meeting of the LBI-CR was held on June 15 - 17, 2014. The researchers presented the recent scientific ouput to the scientific advisors and partners, who voiced their unanimous satisfaction about the quality of the research activities at the institute. Moreover, the scientific advisors appeared impressed with recent organisational developments, which include the appointment of the junior group leader Florian Grebien to the institute and the integration of three researchers into the partner universisties as endowed professors.

Mag. Georg Kapsch, President of the Federation of Austrian Industries visits LBI-CR

Prof. Richard Moriggl welcomes Mag. Georg Kapsch at the LBI-CR

 

Mag. Claudia Lingner, DI Josef Pröll, Prof. Richard Moriggl supported by staff of the LBI-CR hosted Mag. Georg Kapsch, the president of the Federation of Austrian Industries on June 2, 2014. Mag. Kapsch showed himself impressed by the possibilities of modern cancer research and showed particular interest for the potential of novel cancer models generated through genetic modification.

Team of Lukas Kenner receives prestigious Novartis-Award of the DGP

The research team of Lukas Kenner received the prestigious Novartis-Award of the German Society of Pathology (Deutschen Gesellschaft für Pathologie e.V., DGP) for their outstanding work entitled „PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas" published in Nature Medicine. Former co-worker Dr. Laimer received the award personally on June 12 in Berlin during the 98th annual meeting of the DGP.

Current Report

Since 2005 the LBI-CR has evolved into one of Austria's internationally visible scientific institutions in cancer research. With the creation of three endowed professorships by the Medical University Vienna and the University for Veterinary Medicine, Vienna in cooperation with the LBG the integration of the established center of excellence into the Austrian scientific community is under way.

Of mice and men

Richard Moriggl accepted an endowed professorship on "translational methods in cancer research" and gave an interview to the daily "Der Standard" at this occasion, which is available below in German only.

LBI-CR at the "Austrian Researchers' Night"

Prof. Emilio Casanova explains the use of DNA in modern cancer research.

On Friday April, 4 once again the Austrian Researchers' Night 2014 took place. From 5:00 pm onwards researchers of the LBI-CR presented the station "Where does cancer come from?" at the Campus of the Medcal Univeristy Vienna. Many visitors isolated DNA from Kiwifruit, and the very little ones used lab-pipettes to cexplore the effects of pH changes. In addition we made tumor-samples available to be viewed through a microscope. Many visitors discussed with researchers about modern medical research and how it helps to tackle cancer. We thank all visitors for stopping by and the interested questions.

New team leader joins LBI-CR

Florian Grebien joins LBI-CR as team leader to develop his independent research programme in acute myeloid leukemia (AML) in January 2014.

He completed his postdoctoral research in the team of Giulio Superti-Furga at the Research Centre for Molecular Medicine and will continue his outstanding research to elucidate the mechanistic basis of leukemogenesis.His team will be using a multidisciplinary approach, deploying a number of modern techniques, including shRNA and drug screening, expression profiling and proteomics. Within the forthcoming years, Dr. Grebien will develop a strong independent research team with international visibility, benefitting from the full support of the LBI-CR and the stimulating research environment provided by the LBI-CR's partner institutions. With this appointment the LBI-CR creates an attractive opportunity for an outstanding Austrian young research talent with the support of the LBG .

Please see the career section for current recruitments of the Grebien team.

Pages